Moderna has been granted a patent for a method of treating cancer by administering a lipid nanoparticle containing messenger RNA encoding a tethered interleukin-12 polypeptide. This innovative approach aims to reduce tumor size or inhibit tumor growth in patients. GlobalData’s report on Moderna gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Moderna, mRNA delivery lipid nanoparticles was a key innovation area identified from patents. Moderna's grant share as of January 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Lipid nanoparticle for il-12 mrna cancer treatment
A recently granted patent (Publication Number: US11873327B2) discloses a method for treating cancer by administering a lipid nanoparticle (LNP) containing messenger RNA (mRNA) encoding a human interleukin-12 (IL-12) polypeptide linked to a membrane domain. The IL-12 polypeptide consists of IL-12 p40 and IL-12 p35 subunits linked to transmembrane domains like CD80, PDGFR, or CD8, aiming to reduce tumor size or inhibit tumor growth in the subject. The method involves various configurations of the IL-12 polypeptide, peptide linkers, microRNA binding sites, and chemical modifications in the mRNA to enhance therapeutic efficacy.
Furthermore, the patent details the composition of LNPs, including ionizable amino lipids, phospholipids, sterols, and PEG-modified lipids, in specific molar ratios. The method also encompasses the administration of a second mRNA encoding a different polypeptide to enhance the treatment's effectiveness. The mRNA sequences, peptide linkers, and membrane domain configurations specified in the claims aim to optimize the delivery and expression of IL-12 for cancer treatment. The inclusion of microRNA binding sites and chemical modifications in the mRNA further highlights the innovative approach to modulating gene expression for therapeutic purposes. The intratumoral administration of LNPs underscores the localized delivery of the therapeutic payload for targeted cancer treatment, potentially minimizing systemic side effects.
To know more about GlobalData’s detailed insights on Moderna, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
